{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:23:27Z","timestamp":1776090207704,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s10549-013-2574-2","type":"journal-article","created":{"date-parts":[[2013,7,22]],"date-time":"2013-07-22T14:35:16Z","timestamp":1374503716000},"page":"341-351","source":"Crossref","is-referenced-by-count":54,"title":["Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy"],"prefix":"10.1007","volume":"140","author":[{"given":"Linda T.","family":"Vahdat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agustin A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah L.","family":"Lindquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Iannotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashanth","family":"Gopalakrishna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Sparano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,23]]},"reference":[{"key":"2574_CR1","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1158\/0008-5472.CAN-04-1169","volume":"64","author":"G Kuznetsov","year":"2004","unstructured":"Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, Kishi Y, Yu MJ, Littlefield BA (2004) Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 64:5760\u20135766","journal-title":"Cancer Res"},{"key":"2574_CR2","first-page":"1013","volume":"61","author":"MJ Towle","year":"2001","unstructured":"Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsky BM, Palme MH, Habgood GJ, Singer LA, Dipietro LV, Wang Y, Chen JJ, Quincy DA, Davis A, Yoshimatsu K, Kishi Y, Yu MJ, Littlefield BA (2001) In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 61:1013\u20131021","journal-title":"Cancer Res"},{"key":"2574_CR3","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","volume":"4","author":"MA Jordan","year":"2005","unstructured":"Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4:1086\u20131095","journal-title":"Mol Cancer Ther"},{"key":"2574_CR4","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1158\/1535-7163.MCT-08-0095","volume":"7","author":"T Okouneva","year":"2008","unstructured":"Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA (2008) Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 7:2003\u20132011","journal-title":"Mol Cancer Ther"},{"key":"2574_CR5","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1021\/bi901810u","volume":"49","author":"JA Smith","year":"2010","unstructured":"Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, Jordan MA (2010) Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 49:1331\u20131337","journal-title":"Biochemistry"},{"key":"2574_CR6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1158\/0008-5472.CAN-10-1874","volume":"71","author":"MJ Towle","year":"2011","unstructured":"Towle MJ, Salvato KA, Wels BF, Aalfs KK, Zheng W, Seletsky BM, Zhu X, Lewis BM, Kishi Y, Yu MJ, Littlefield BA (2011) Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res 71:496\u2013505","journal-title":"Cancer Res"},{"key":"2574_CR7","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Di\u00e9ras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C (2011) Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open-label randomised study. Lancet 377:914\u2013923","journal-title":"Lancet"},{"key":"2574_CR8","unstructured":"Eisai Inc (2012) Halaven prescribing information. http:\/\/www.halaven.com\/ . Accessed 1 Feb 2013"},{"key":"2574_CR9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/clpt.2011.115","volume":"90","author":"DR Pachman","year":"2011","unstructured":"Pachman DR, Barton DL, Watson JC, Loprinzi CL (2011) Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 90:377\u2013387","journal-title":"Clin Pharmacol Ther"},{"key":"2574_CR10","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1007\/s00520-011-1365-8","volume":"20","author":"RM Speck","year":"2012","unstructured":"Speck RM, Demichele A, Farrar JT, Hennessy S, Mao JJ, Stineman MG, Barg FK (2012) Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients. Support Care Cancer 20:2433\u20132439","journal-title":"Support Care Cancer"},{"key":"2574_CR11","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.2008.17.7618","volume":"27","author":"LT Vahdat","year":"2009","unstructured":"Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, Dacosta NA, Chuang E, Smith J, O\u2019Shaughnessy J, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Cole PE, Ashworth S, Blum JL (2009) Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 27:2954\u20132961","journal-title":"J Clin Oncol"},{"key":"2574_CR12","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1200\/JCO.2009.25.8467","volume":"28","author":"J Cortes","year":"2010","unstructured":"Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roch\u00e9 H, Bachelot T, Awada A, Paridaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA (2010) Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 28:3922\u20133928","journal-title":"J Clin Oncol"},{"key":"2574_CR13","first-page":"1429","volume":"7","author":"FY Lee","year":"2001","unstructured":"Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA (2001) BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429\u20131437","journal-title":"Clin Cancer Res"},{"key":"2574_CR14","unstructured":"Bristol-Myers Squibb Company (2011) IXEMPRA\u2122 Kit (ixabepilone) for Injection prescribing information. http:\/\/packageinserts.bms.com\/pi\/pi_ixempra.pdf . Accessed 1 Feb 2013"},{"key":"2574_CR15","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1200\/JCO.2006.08.9102","volume":"25","author":"E Thomas","year":"2007","unstructured":"Thomas E, Tabernero J, Fornier M, Cont\u00e9 P, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, Baselga J, Rivera E, Guarneri V, Poulart V, Klimovsky J, Lebwohl D, Martin M (2007) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 25:3399\u20133406","journal-title":"J Clin Oncol"},{"key":"2574_CR16","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1200\/JCO.2006.09.3849","volume":"25","author":"EA Perez","year":"2007","unstructured":"Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P, Cai C, Mullaney B, Peck R, Hortobagyi GN (2007) Efficacy and safety of ixabepilone (BMS-247550) in a Phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25:3407\u20133414","journal-title":"J Clin Oncol"},{"key":"2574_CR17","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1200\/JCO.2006.09.7535","volume":"25","author":"H Roch\u00e9","year":"2007","unstructured":"Roch\u00e9 H, Yelle L, Cognetti F, Mauriac L, Bunnell C, Sparano J, Kerbrat P, Delord JP, Vahdat L, Peck R, Lebwohl D, Ezzeddine R, Cur\u00e9 H (2007) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 25:3415\u20133420","journal-title":"J Clin Oncol"},{"key":"2574_CR18","doi-asserted-by":"crossref","first-page":"CRA1002","DOI":"10.1200\/jco.2012.30.18_suppl.cra1002","volume":"30","author":"HS Rugo","year":"2012","unstructured":"Rugo HS, Barry W, Moreno-Aspitia A, Lyss AP, Cirrincione C, Mayer EL, Naughton M, Layman RM, Carey LA, Somer RA, Perez EA, Hudis C, Winer EP (2012) CALGB 40502\/NCCTG N063H: Randomized Phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 30:CRA1002","journal-title":"J Clin Oncol"},{"key":"2574_CR19","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1158\/0008-5472.CAN-10-4184","volume":"71","author":"KM Wozniak","year":"2011","unstructured":"Wozniak KM, Nomoto K, Lapidus RG, Wu Y, Carozzi V, Cavaletti G, Hayakawa K, Hosokawa S, Towle MJ, Littlefield BA, Slusher BS (2011) Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice. Cancer Res 71:3952\u20133962","journal-title":"Cancer Res"},{"key":"2574_CR20","unstructured":"LaPointe NE, Wilson L, Feinstein SC, Jordan M (2011) Effects of eribulin, vincristine, paclitaxel, and ixabepilone on kinesin-driven microtubule gliding. Presented at Society for Neuroscience National Meeting, Washington DC, USA, 12\u201316 Nov 2011, poster 367.01"},{"key":"2574_CR21","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1007\/s00520-012-1384-0","volume":"20","author":"LT Vahdat","year":"2012","unstructured":"Vahdat LT, Thomas ES, Roch\u00e9 HH, Hortobagyi GN, Sparano JA, Yelle L, Fornier MN, Martin M, Bunnell CA, Mukhopadhyay P, Peck RA, Perez EA (2012) Ixabepilone-associated peripheral neuropathy: data from across the Phase II and III clinical trials. Support Care Cancer 20:2661\u20132668","journal-title":"Support Care Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-013-2574-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-013-2574-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-013-2574-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T02:18:26Z","timestamp":1563502706000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-013-2574-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["2574"],"URL":"https:\/\/doi.org\/10.1007\/s10549-013-2574-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}